+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07717242

Evaluation of Disitamab Vedotin and Toripalimab with Four Sensitizing Agents in HER2-Positive Muscle-Invasive Bladder Cancer

Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2026-07-21

80

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying different strategies to improve treatment for patients with HER2-positive muscle-invasive urothelial carcinoma of the bladder MIBC. This Phase II, open-label trial evaluates the safety and effectiveness of combining the drugs disitamab vedotin and toripalimab with one of four sensitizing agents. The goal is to see if these combinations can increase the rate of complete clinical response and help preserve the bladder in patients with this type of bladder cancer. Participants will receive neoadjuvant treatment with disitamab vedotin and toripalimab every two weeks, combined with one sensitizing agent sitagliptin, tazemetostat, tafolecimab, or ursodeoxycholic acid. This treatment lasts for 6 cycles over about 3 months. After neoadjuvant therapy, patients undergo a complete transurethral resection of bladder tumor cTURBT and other assessments to evaluate response. Those with a complete clinical response may continue with additional cycles of the drugs and maintenance therapy with toripalimab for up to one year. Patients without complete response may have salvage radical cystectomy surgery. Throughout the study, participants will have imaging, pathology, and urine tests to monitor treatment effects. Researchers will assess response rates, bladder preservation, survival outcomes, safety, quality of life, and treatment costs over up to 5 years. Adverse events will be monitored for up to 18 months after the last treatment. The study involves multiple visits and procedures to ensure thorough evaluation and follow-up of participants.

CONDITIONS

Brief Title

Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

Research Team

W

Wenlong Zhong, Professor

M

Mingli Luo, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here